Ayvakit, Ayvakyt(avapritinib)
Ayvakit, Ayvakyt (avapritinib) is a small molecule pharmaceutical. Avapritinib was first approved as Ayvakit on 2020-01-09. It is used to treat gastrointestinal stromal tumors in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors. It is known to target mast/stem cell growth factor receptor Kit.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Ayvakit
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avapritinib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AYVAKIT | Blueprint Medicines | N-212608 RX | 2020-01-09 | 5 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ayvakit | New Drug Application | 2024-05-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| gastrointestinal stromal tumors | EFO_0000505 | D046152 | C49.A |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AVAPRITINIB, AYVAKIT, BLUEPRINT MEDICINES | |||
| 2030-05-22 | ODE-434 | ||
| 2028-06-16 | ODE-356 | ||
| 2027-01-09 | ODE-366 | ||
| 2026-05-22 | I-912 | ||
| 2025-01-09 | NCE | ||
| 2024-06-16 | I-863, I-864 | ||
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 3 | 1 | 1 | 1 | 5 | 10 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 3 | — | — | 3 | 10 |
| Systemic mastocytosis | D034721 | — | C96.21 | 2 | 2 | — | — | 1 | 5 |
| Mastocytosis | D008415 | — | D47.09 | 2 | 2 | — | — | 1 | 5 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | 1 | 3 |
| Mast-cell leukemia | D007946 | — | C94.3 | 1 | 1 | — | — | 1 | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 3 | — | — | — | 3 |
| Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 2 |
| Sarcoma | D012509 | — | — | 1 | 1 | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | 1 | 2 |
Show 10 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Avapritinib |
| INN | avapritinib |
| Description | Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and for the treatment of tumors due to one specific rare mutation: it is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. Avapritinib is a kinase inhibitor.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 1703793-34-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4204794 |
| ChEBI ID | — |
| PubChem CID | 118023034 |
| DrugBank | DB15233 |
| UNII ID | 513P80B4YJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KIT
KIT
Organism
Homo sapiens
Gene name
KIT
Gene synonyms
SCFR
NCBI Gene ID
Protein name
mast/stem cell growth factor receptor Kit
Protein synonyms
c-Kit protooncogene, CD117, p145 c-kit, PBT, Piebald trait protein, Proto-oncogene c-Kit, proto-oncogene tyrosine-protein kinase Kit, Tyrosine-protein kinase Kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein
Uniprot ID
Mouse ortholog
Kit (16590)
mast/stem cell growth factor receptor Kit (Q8C8K9)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Ayvakit – Blueprint Medicines
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 820 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,570 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use